BTVPUR AlSap 2-4

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

bolezen modrikastega jezika-virus serotip-2 antigen, bolezen modrikastega jezika-virus serotip-4 antigen

Available from:

Mérial

ATC code:

QI04AA02

INN (International Name):

inactivated adjuvanted vaccine against bluetongue virus serotype 2 and 4 infections

Therapeutic group:

Ovce

Therapeutic area:

bolezen modrikastega jezika virus, Inaktivirano virusna cepiva, Immunologicals za ovidae

Therapeutic indications:

Aktivna imunizacija ovac za preprečevanje viremije in zmanjšanje kliničnih znakov, ki jih povzročajo serotipi 2 in 4 virusa bolezni modrikastega jezika.

Product summary:

Revision: 4

Authorization status:

Umaknjeno

Authorization date:

2010-11-04

Patient Information leaflet

                                19
B. NAVODILO ZA UPORABO
Zdravilo nima veā dovoljenja za promet
20
NAVODILO ZA UPORABO
BTVPUR ALSAP 2-4 SUSPENZIJA ZA INJICIRANJE ZA OVCE
1.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER
IMETNIKA DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVORNEGA ZA
SPROSTITEV SERIJE V EGP, ČE STA RAZLIČNA
Imetnik dovoljenja za promet z zdravilom:
MERIAL
29 avenue Tony Garnier
69007 Lyon,
Francija
Izdelovalec, odgovoren za sprostitev serije:
MERIAL
Laboratory of Lyon Porte des Alpes
Rue de l’Aviation,
69800 Saint-Priest
Francija
2.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
BTVPUR AlSap 2-4 suspenzija za injiciranje za ovce
3.
NAVEDBA ZDRAVILNE(IH) UČINKOVIN(E) IN DRUGEIH SESTAVIN
Vsak odmerek (1 ml) cepiva vsebuje:
Virus modrega jezika, serotip 2, antigen
.......................................................................
6,8–9,5 CCID
50
*,
Virus modrega jezika, serotip 4, antigen
.......................................................................
7,1–8,5 CCID
50
*,
Aluminijev hidroksid
2,7 mg,
Saponin
30 HE**.
*Infektivni odmerek za celično kulturo 50%, ekvivalent titru pred
inaktivacijo (log
10
)
**Hemolizne enote.
4.
INDIKACIJA(E)
Aktivna imunizacija ovc proti virusu modrega jezika, serotip 2 in 4,
za preprečitev viremije* in
zmanjšanje kliničnih znakov.
*pod stopnjo detekcije z validirano metodo RT-PCR pri 3,68 log
10
RNA kopijah/ml, ni prenosa virusa
Imunost nastopi tri tedne po osnovnem cepljenju za serotip 4 in 5
tednov po osnovnem cepljenju za
serotip 2.
Trajanje imunosti 1 leto po osnovnem cepljenju.
5.
KONTRAINDIKACIJE
Jih ni.
Zdravilo nima veā dovoljenja za promet
21
6.
NEŽELENI UČINKI
Po cepljenju se lahko na mestu dajanja pojavi prehodna manjša
lokalizirana oteklina (največ 24 cm
2
),
ki hitro izgine (v največ 14 dneh).
Do 24 ur po cepljenju je možen pojav prehodnega povišanja telesne
temperature, ki navadno ne
preseže 1,1 °C.
Če opazite kakršne koli resne neželene učinke ali druge učinke,
ki niso omenjeni v teh navodilih za
uporabo, obvestite svojega veterinarja.
7
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
DODATEK I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
Zdravilo nima veā dovoljenja za promet
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 13-11-2018
Summary of Product characteristics Summary of Product characteristics Bulgarian 13-11-2018
Public Assessment Report Public Assessment Report Bulgarian 13-11-2018
Patient Information leaflet Patient Information leaflet Spanish 13-11-2018
Public Assessment Report Public Assessment Report Spanish 13-11-2018
Patient Information leaflet Patient Information leaflet Czech 13-11-2018
Public Assessment Report Public Assessment Report Czech 13-11-2018
Patient Information leaflet Patient Information leaflet Danish 13-11-2018
Public Assessment Report Public Assessment Report Danish 13-11-2018
Patient Information leaflet Patient Information leaflet German 13-11-2018
Public Assessment Report Public Assessment Report German 13-11-2018
Patient Information leaflet Patient Information leaflet Estonian 13-11-2018
Public Assessment Report Public Assessment Report Estonian 13-11-2018
Patient Information leaflet Patient Information leaflet Greek 13-11-2018
Public Assessment Report Public Assessment Report Greek 13-11-2018
Patient Information leaflet Patient Information leaflet English 13-11-2018
Public Assessment Report Public Assessment Report English 13-11-2018
Patient Information leaflet Patient Information leaflet French 13-11-2018
Public Assessment Report Public Assessment Report French 13-11-2018
Patient Information leaflet Patient Information leaflet Italian 13-11-2018
Public Assessment Report Public Assessment Report Italian 13-11-2018
Patient Information leaflet Patient Information leaflet Latvian 13-11-2018
Public Assessment Report Public Assessment Report Latvian 13-11-2018
Patient Information leaflet Patient Information leaflet Lithuanian 13-11-2018
Summary of Product characteristics Summary of Product characteristics Lithuanian 13-11-2018
Public Assessment Report Public Assessment Report Lithuanian 13-11-2018
Patient Information leaflet Patient Information leaflet Hungarian 13-11-2018
Summary of Product characteristics Summary of Product characteristics Hungarian 13-11-2018
Public Assessment Report Public Assessment Report Hungarian 13-11-2018
Patient Information leaflet Patient Information leaflet Maltese 13-11-2018
Public Assessment Report Public Assessment Report Maltese 13-11-2018
Patient Information leaflet Patient Information leaflet Dutch 13-11-2018
Public Assessment Report Public Assessment Report Dutch 13-11-2018
Patient Information leaflet Patient Information leaflet Polish 13-11-2018
Public Assessment Report Public Assessment Report Polish 13-11-2018
Patient Information leaflet Patient Information leaflet Portuguese 13-11-2018
Summary of Product characteristics Summary of Product characteristics Portuguese 13-11-2018
Public Assessment Report Public Assessment Report Portuguese 13-11-2018
Patient Information leaflet Patient Information leaflet Romanian 13-11-2018
Public Assessment Report Public Assessment Report Romanian 13-11-2018
Patient Information leaflet Patient Information leaflet Slovak 13-11-2018
Public Assessment Report Public Assessment Report Slovak 13-11-2018
Patient Information leaflet Patient Information leaflet Finnish 13-11-2018
Public Assessment Report Public Assessment Report Finnish 13-11-2018
Patient Information leaflet Patient Information leaflet Swedish 13-11-2018
Public Assessment Report Public Assessment Report Swedish 13-11-2018
Patient Information leaflet Patient Information leaflet Norwegian 13-11-2018
Summary of Product characteristics Summary of Product characteristics Norwegian 13-11-2018
Patient Information leaflet Patient Information leaflet Icelandic 13-11-2018
Summary of Product characteristics Summary of Product characteristics Icelandic 13-11-2018
Patient Information leaflet Patient Information leaflet Croatian 13-11-2018